GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agentix Corp (OTCPK:AGTX) » Definitions » Cyclically Adjusted Price-to-FCF

Agentix (Agentix) Cyclically Adjusted Price-to-FCF : (As of Jun. 08, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Agentix Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Agentix Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Agentix's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agentix Cyclically Adjusted Price-to-FCF Chart

Agentix Annual Data
Trend Aug14 Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Mar23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only - - - - -

Agentix Quarterly Data
Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Agentix's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Agentix's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Agentix's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Agentix's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Agentix's Cyclically Adjusted Price-to-FCF falls into.



Agentix Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Agentix's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Agentix's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.001/129.4194*129.4194
=-0.001

Current CPI (Dec. 2023) = 129.4194.

Agentix Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201402 -0.072 99.057 -0.094
201405 -0.119 100.373 -0.153
201408 -0.069 100.352 -0.089
201411 -0.106 99.635 -0.138
201502 -0.116 99.032 -0.152
201505 -0.059 100.333 -0.076
201508 -0.033 100.548 -0.042
201511 -0.012 100.135 -0.016
201602 0.002 100.040 0.003
201605 -0.010 101.355 -0.013
201608 -0.002 101.617 -0.003
201611 -0.035 101.829 -0.044
201702 -0.023 102.779 -0.029
201705 -0.050 103.256 -0.063
201708 -0.020 103.587 -0.025
201711 -0.045 104.072 -0.056
201802 0.000 105.052 0.000
201805 -0.001 106.148 -0.001
201808 -0.011 106.383 -0.013
201811 -0.019 106.338 -0.023
201902 -0.011 106.649 -0.013
201905 -0.010 108.048 -0.012
201908 0.000 108.245 0.000
201911 0.000 108.519 0.000
202002 0.000 109.139 0.000
202005 0.000 108.175 0.000
202008 0.000 109.662 0.000
202011 -0.007 109.793 -0.008
202102 -0.003 110.968 -0.003
202105 -0.003 113.576 -0.003
202108 0.000 115.421 0.000
202111 0.000 117.269 0.000
202202 0.000 119.703 0.000
202206 0.000 125.017 0.000
202209 -0.001 125.227 -0.001
202212 0.000 125.222 0.000
202303 0.000 127.348 0.000
202306 -0.002 128.729 -0.002
202309 0.001 129.860 0.001
202312 -0.001 129.419 -0.001

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Agentix  (OTCPK:AGTX) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Agentix Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Agentix's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Agentix (Agentix) Business Description

Industry
Traded in Other Exchanges
N/A
Address
32932 Pacific Coast Highway, Suite 14-254, Dana Point, CA, USA, 92629
Agentix Corp is a biotechnology company. It is engaged in the development and commercialization of novel therapeutics to treat metabolic diseases, peripheral neuropathy, progressive lung disease, and ischemic reperfusion injury. Its principal business objective is to develop both science-driven synthetic and natural cannabinoid therapeutics that address unmet medical needs and continue to drive innovations in the endocannabinoid space.
Executives
Thomas E Puzzo 10 percent owner 4216 NE 70TH STREET, SEATTLE WA 98115
Michael Winterhalter director, 10 percent owner, officer: President, CEO, CFO, Treasurer 32932 PACIFIC COAST HIGHWAY, #14-254, DANA POINT CA 92629
Grays Peak Ventures Llc 10 percent owner 320 PARK AVE, NEW YORK NY 10022
Scott B Stevens director, officer: President and Director 9701 WILSHIRE BLVD., SUITE 1000, BEVERLY HILLS CA 90212
Robert K Whalen director, officer: Secretary and Treasurer 32932 PACIFIC COAST HIGHWAY, #14-254, DANA POINT CA 92629
Scott Thomas director 14 MONARCH BEACH PLAZA, SUITE 254, MONARCH BEACH CA 92629
Robert Drust director 14 MONARCH BEACH PLAZA, SUITE 254, MONARCH BEACH CA 92629
Eric Krogius director, 10 percent owner 32932 PACIFIC COAST HIGHWAY, #14-254, DANA POINT CA 92629
Bao Dong Han 10 percent owner 32932 PACIFIC COAST HIGHWAY, #14-254, DANA POINT CA 92629

Agentix (Agentix) Headlines

No Headlines